Measurement of afucosylated IgG Fc glycans and related vaccination methods
View Patent ↗The present disclosure provides methods related to determining the level of afucosylated Fc glycans in IgG antibodies in a biological sample from a subject. This level can be used in methods aimed at monitoring and/or treating subject suffering from an acute flavivirus infection and/or who are at risk for progression to clinically significant infection or disease. This level can also be used in a vaccination method to ensure that those who receive a flavivirus vaccine have a reduced risk of reacting to the vaccine be developing clinically significant infection or disease. The disclosure also provides treatment methods based on inhibiting FcγRIIA or FcγRIIIA receptor signaling. Also provided are novel cell lines that are useful in measuring afucosylated Fc glycans.
1. A vaccination method, the method comprising:
(a) performing an assay to determine a level of afucosylated Fc glycans in IgG antibodies in a biological sample from a subject or in a biological sample from mother of an infant subject, thereby identifying the subject not having 5 percent or greater of the IgG antibodies having the afucosylated Fc glycans in the biological sample from the subject, or identifying the infant subject with the mother not having 5 percent or greater of the IgG antibodies of the IgG antibodies having the afucosylated Fc glycans in the biological sample from the mother of the infant subject; and
vaccinating against a Dengue virus the subject or the infant subject identified in step (a).
2. The vaccination method of claim 1 , wherein the IgG antibodies are IgG1 antibodies.
3. The vaccination method of claim 1 , wherein the IgG antibodies are IgG antibodies specific for a Dengue virus antigen.
4. The vaccination method of claim 1 , wherein the 5 percent or greater is as 10 percent or greater.
5. The vaccination method of claim 1 , wherein the vaccinating is vaccinating the infant subject.
6. The method of claim 1 , wherein the IgG antibodies are IgG antibodies of all specificities.
7. The vaccination method of claim 1 , wherein the subject is a human.
8. The method of claim 5 , wherein the mother of the infant subject has IgG antibodies that are reactive with the Dengue virus.
9. The vaccination method of claim 1 , wherein the biological sample is blood or a blood fraction.